Developing innovative strategies for advanced transitional cell carcinoma of the bladder.

about

Developing innovative strategies for advanced transitional cell carcinoma of the bladder.

Item

http://www.wikidata.org/entity/Q36352085

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Developing innovative strategies for advanced transitional cell carcinoma of the bladder.

@ast

Developing innovative strategies for advanced transitional cell carcinoma of the bladder.

@en

type

Item

label

Developing innovative strategies for advanced transitional cell carcinoma of the bladder.

@ast

Developing innovative strategies for advanced transitional cell carcinoma of the bladder.

@en

prefLabel

Developing innovative strategies for advanced transitional cell carcinoma of the bladder.

@ast

Developing innovative strategies for advanced transitional cell carcinoma of the bladder.

@en

P1476

Developing innovative strategies for advanced transitional cell carcinoma of the bladder.

@en

P2093

Camillo F Pollera

http://www.w3.org/2001/XMLSchema#string

Fabrizio Nelli

http://www.w3.org/2001/XMLSchema#string

P2860

Protein prenyltransferases

Cancer statistics, 2005

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.

Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?

P304

83-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.6.1.83

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16375647

http://www.w3.org/2001/XMLSchema#string